New insights into cytotoxic effector cells;Les effecteurs cytotoxiques: Données récentes

Bulletin du Cancer

Volumn 92, Issue 11, 2005, Pages 935-943

  Rey, J ^a   Olive, D ^a,b   Sebahounn G ^c   O'Callaghan, T ^c   Costello, Régis T ^c  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

^c HÔPITAL NORD   (France)

Author keywords

Anti tumor immunity; Cytotoxic T lymphocyte; Immunotherapy; Natural killer cell; NKT cell; T lymphocyte

Indexed keywords

CANCER INVASION; CELL FUNCTION; CELL POPULATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; NATURAL KILLER CELL; REVIEW; SUPPRESSOR CELL; TUMOR CELL; TUMOR IMMUNITY;

CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 29344443791     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Santamaria P. Effector lymphocytes in autoimmunity. Curr Opin Immunol 2001; 13: 663-9.
2. Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha (1) beta (2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 2002; 168: 1831-9.
3. Screpanti V, Wallin RP, Grandien A, Ljunggren HG. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 2005; 42: 495-9.
4. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-12.
5. + T cells closely correlates with CD56 surface expression. J Immunol 2000; 164: 1148-52.
6. + effector αβ T cells. J Immunol 2001; 16: 6165-70.
7. Romero P, Cerottini JC, Waanders GA. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol Med Today 1998; 4: 305-12.
8. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255-60.
9. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, et al. Characterization of CD4 (+) CTLs ex vivo. J Immunol 2002; 168: 5954-8.
10. Namekawa T, Snyder MR, Yen JH, Goehring BE, Leibson JL, Weyand CW, et al. Killer cell activating receptors function as costimulatory molecules on CD4+ CD28null T cells clonally expanded in rheumatoid arthritis. J Immunol 2000; 165: 1138-45.
11. Hamidou M, Lamy T. Chronic proliferation of large granular lymphocytes. Rev Med Interne 2001; 22: 452-9.
12. Costello RT, Sivori S, Mallet F, Sainty D, Arnoulet C, Reviron D, et al. A novel mechanism of antitumor response involving the expansion of CD3+/CD56+ large granular lymphocytes triggered by a tumor-expressed activating ligand. Leukemia 2002; 16: 855-60.
13. Handgretinger R, Geiselhart A, Moris A, Grau R, Teuffel O, Bethge W, et al. Pure red-cell aplasia associated with clonal expansion of large granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med 1999; 340: 278-84.
14. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285-94.
15. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001; 98: 2736-44.
16. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001; 193: F41-F46.
17. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+ CD25+ immunoregulatory cells. J Immunol 2001; 167: 1137-40.
18. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303-10.
19. Ramsdell F. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 2003; 19: 165-8.
20. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999; 17: 875-904.
21. Mingari MC, Schiavetti F, Ponte M, Vitale C, Maggi E, Romagnani S, et al. Human CD8 + T lymphocyte subsets that express HLA class I- specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci USA 1996; 93: 12433-8.
22. Mingari MC, Moretta A, Moretta L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell response. Immunol Today 1998; 19: 153-7.
23. McMahon CW, Raulet DH. Expression and function of NK cell receptors in CD8+ T cells. Curr Opin Immunol 2001; 13: 465-70.
24. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000; 290: 84-9.
25. De Maria A, Ferraris A, Guastella M, Pilia S, Cantoni C, Polero L, et al. Expression of HLA class I-specific inhibitory natural killer cell receptors in HIV-specific cytolytic T lymphocytes: impairment of specific cytolytic functions. Proc Natl Acad Sci USA 1997; 94: 10285-8.
26. Costa P, Rusconi S, Mavilio D, Fogli M, Murdaca G, Pende D, et al. Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxic T lymphocytes. AIDS 2001; 15: 965-74.
27. Speiser DE, Pittet MJ, Valmori D, Dunbar R, Rimoldi D, Lienard D, et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med 1999; 190: 775-82.
28. Guerra N, Guillard M, Angevin E, Echchakir H, Escudier B, Moretta A, et al. Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas. Blood 2000; 95: 2883-9.
29. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-47.
30. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1: 41-9.
31. Moretta A, Biassoni R, Bottino C, Moretta L. Surface receptors delivering opposite signals regulate the function of human NK cells. Semin Immunol 2000; 12: 129-38.
32. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14: 619-48.
33. Lanier LL, Phillips JH. Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today 1996; 17: 86-91.
34. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19: 197-223.
35. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. Natural cytotoxicity receptors that trigger human NK-mediated cytolysis. Immunol Today 2000; 21: 228-34.
36. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress- inducible MICA. Science 1999; 285: 727-9.
37. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-33.
38. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-71.
39. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001; 31: 1076-86.
40. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000; 1: 119-26.
41. Tangye SG, Cherwinski H, Lanier LL, Phillips JH. 2B4-mediated activation of human natural killer cells. Mol Immunol 2000; 37: 493-501.
42. Costello RT, Gastaut JA, Olive D. Mechanisms of tumor escape from immunologic response. Rev Med Interne 1999; 20: 579-88.
43. Gaspar HB, Sharifi R, Gilmour K, Thrasher AJ. X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspecrive. Br J Haematol 2002; 119: 585-95.
44. Kuppen PJ, Gorter A, Hagenaars M, Jonges LE, Giezeman-Smits KM, Nagelkerke JF, et al. J. Role of NK cells in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat model. Immunol Rev 2001; 184: 236-43.
45. Canoz O, Belenli O, Patiroglu TE. General features of gastric carcinomas and comparison of HSP70 and NK cell immunoreactivity with prognostic factors. Pathol Oncol Res 2002; 8: 262-9.
46. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-71.
47. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-9.
48. Hayday AC. Gammadelta cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18: 975-1026.
49. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, et al. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 2005; 174: 1338-47.
50. Granel B, Camoin L, Serratrice J, Roux-Serratrice C, Brunet C, Pache X, et al. Retrospective study of 55 patients with circulating blood T gamma/delta lymphocytosis. Rev Med Int 2002; 23: 137-43.
51. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-84.
52. Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T, et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001; 15: 83-93.
53. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998; 279: 1737-40.
54. Fisch P, Moris A, Rammensee HG, Handgretinger R. Inhibitory MHC class I receptors on gammadelta T cells in tumour immunity and autoimmu-nity. Immunol Today 2000; 21: 187-91.
55. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996; 93: 12445-50.
56. GirardiM, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gamma delta T cells. Science 2001; 294: 605-9.
57. Hayday A, Geng L. Gamma delta cells regulate autoimmunity. Curr Opin Immunol 1997; 9: 884-9.
58. Riccieri V, Spadaro A, Parisi G, Taccari E, Moretti T, Bernardini G, et al. Down-regulation of natural killer cells and of gamma/delta T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity? Lupus 2000; 9: 333-7.
59. Shigehara K, Shijubo N, Nakanishi N, Hirasawa M, Inuzuka M, Ohmichi M, et al. Circulating gamma delta-T-cell receptor-positive lymphocytes in sarcoidosis. Respiration (Herrlisheim) 1995; 62: 84-8.
60. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002; 2: 557-68.
61. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21: 573-83.
62. Kojo S, Adacgi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18 +, BV11 double negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001; 44: 1127-38.
63. Sumida T, Sakamoto A, Murata H, Makino Y, Takahashi H, Yoshida S, et al. Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis. J Exp Med 1995; 182: 1163-8.
64. Mohty M, Gaugler B, Calmels B, Blaise D, Vey N, Chabannon C, et al. Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches. Bull Cancer 2003; 90: 751-7.
65. Benchetrit F, Gazagne A, Adotevi O, Haicheur N, Godard B, Badoual C, et al. Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy. Bull Cancer 2003; 90: 677-85.
66. Costello R, Gastaut JA, Olive D. Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz) 1999; 47: 83-8.
67. Costello R, Gastaut JA, Olive D. Mécanismes d'échappement tumoral à la réponse immunitaire. Rev Med Int 1999; 20: 579-88.
68. Borg C, Taieb J, Terme M, Maruyama K, Flament C, Angevin E, et al. NK cell-based immunotherapy: new prospects and involvement of dendrite cells. Bull Cancer 2003; 90: 699-705.
69. Abastado JP. Cellular immunotherapy: complexity of immune system and industrial development. Bull Cancer 2003; 90: 789-94.
70. Costello R, Fauriat C, Rey J, Gastaut JA, Olive D. Immunobiology of haematological malignant disorders; the basis for novel immunotherapy protocols. Lancet Oncol 2004; 5: 47-55.